Krishnaraj Rajalingam

Company: University of Mainz

Job title: Founder, KHR Biotec & Head of Cell Biology Unit

Seminars:

Advancing Cancer Therapy Using Natural Compound Derivatives: Mutation Agnostic Targeting of the RAS & MAPK Cascades 12:15 pm

Assessing novel Pan-RAS inhibitors with a unique MoA and providing updates on the clinical development of a promising new therapeutic Validating targets identified by multi-omics analysis of patient materials to enable personalize precision therapy for patients Elucidating the role of atypical MAPKs in human cancers to explore targeting opportunities for enhanced treatment opportunitiesRead more

day: Day Two Track B AM